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The oestrogen receptor-a (ERa) plays a key role in breast development and tumorigenesis and inhibiting its activity remains a prime
strategy in the treatment of ERa-positive breast cancers. Thus, elucidation of the molecular mechanisms responsible for regulating
ERa activity may facilitate the design of new, more effective breast cancer therapies. The MI-ER1a is a novel transcriptional repressor
that contains an LXXLL motif for interaction with nuclear hormone receptors. We investigated the ability of MI-ER1a to bind to ERa
in HEK293 and MCF-7 breast carcinoma cells, using co-immunoprecipitation assays. In both cell lines, MI-ER1a interacted with ERa in
the presence and absence of oestrogen, but the interaction was stronger in the absence of ligand. Functional analysis revealed that
overexpression of MI-ER1a in T47D breast carcinoma cells results in inhibition of oestrogen-stimulated anchorage-independent
growth, suggesting that MI-ER1a may play a role in regulating breast carcinoma cell proliferation in vivo. To explore this further, we
performed an immunohistochemical analysis of normal breast tissue and breast carcinoma; a total of 110 cases were examined in
whole tissue sections and 771 cases were analysed in tissue microarrays. No consistent difference in the MI-ER1a expression level
between normal breast tissue and breast carcinoma was discernible. However, there was a dramatic shift in the subcellular
localisation: nuclear MI-ER1a was detectable in 75% of normal breast samples and in 77% of hyperplasia, but in breast carcinoma, only
51% of DCIS, 25% of ILC and 4% of IDC contained nuclear staining. This shift from nuclear to cytoplasmic localisation of MI-ER1a
during breast cancer progression suggests that loss of nuclear MI-ER1a might contribute to the development of invasive breast
carcinoma.
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Steroid hormones, in particular oestrogens and progesterones, are
crucial not only for normal growth and development of the
mammary gland, but also as growth factors for the large majority
of mammary carcinomas (Anderson, 2002; Clarke et al, 2004).
Indeed, ERa status of breast tumours provides a powerful
prognostic and predictive indicator to guide treatment regimens.
Moreover, therapies that target oestrogen synthesis (oopherectomy:
aromatase inhibitors) and/or that block oestrogen action on its
receptor are critical for the management of hormone-dependent
breast cancers (Arnedos and Smith, 2007).
In the classic pathway, the cellular response to oestrogen is
initiated by hormone binding to ERa (Clarke et al, 2004; Hall and
McDonnell, 2005). This high-affinity binding leads to a conforma-
tional alteration of the receptor, nuclear translocation and homo-
dimerisation of the receptor complex. These changes permit the ERa
complexes to bind sequence-specific oestrogen response elements
located in the regulatory regions of oestrogen target genes, thus
controlling their level of transcription. As with any biological
pathway, this simple scheme is influenced by additional regulatory
mechanisms in the cell (Ascenzi et al, 2006). These include
phosphorylation of ERa, crosstalk with other signal transduction
pathways, interactions with alternate receptor isoforms, like ERb,
and binding of ERa to coactivator and corepressor proteins, all of
which can influence the cell’s transcriptional response to oestrogen.
It is now clear that tumour growth in response to oestrogen and to
anti-oestrogen therapies will depend upon the sum total of
regulatory effects acting on ERa. Thus, understanding the molecular
mechanisms involved in controlling ERa activity in tumour cells will
not only be critical for the development of new markers for
screening and early detection, but also for the identification of
additional prognostic indicators for treatment design and novel
targets for the development of more effective breast cancer therapies.
Mesoderm induction early response 1 is a novel, highly
conserved transcriptional regulator (Paterno et al, 1997, 1998;
Thorne et al, 2005) discovered during a screen for fibroblast
growth factor response genes (Paterno et al, 1997). The MI-ER1
protein includes several domains common to transcriptional
regulators: the N terminus contains four acidic stretches that
function as an acidic activation domain (Paterno et al, 1997).
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sImmediately downstream is an ELM2 domain, followed by a SANT
motif; the ELM2 domain is involved in recruitment of histone
deacetylase (HDAC) activity, which leads to changes in chromatin
structure and results in transcriptional repression (Ding et al,
2003). Likewise, the MI-ER1 SANT domain functions in gene
repression by interacting with Sp1 and interfering with its ability
to bind to its cognate site on responsive promoters (Ding et al,
2004). Thus, MI-ER1 has the ability to function as both activator
and repressor of gene transcription, depending on the cellular
context.
Characterisation of the human mi-er1 gene revealed that
there are two major protein isoforms, MI-ER1a and MI-ER1b,
which differ in their C-terminal sequence (Paterno et al, 2002). Of
particular interest is MI-ER1a, as it contains in its C terminus a
consensus LXXLL interaction domain characteristic of nuclear
hormone receptor (NR) coregulators. Initial expression analysis
indicated that mi-er1 mRNA was differentially expressed in breast
carcinoma cell lines and breast tumours (Paterno et al, 1998);
however this study did not distinguish between the two MI-ER1
isoforms. In the current report, we examined the ability of MI-
ER1a to interact with ERa, its effect on oestrogen-stimulated
growth and its expression pattern in normal human breast tissue
and primary breast carcinoma.
MATERIALS AND METHODS
Cell lines, plasmids and transfections
The cell lines MCF-7 and HEK293 were obtained from the
American Tissue Culture Collection (Manassas, VA, USA); the
T47D Tet-On cell line was purchased from Clontech (Mountain
View, CA, USA). All cell lines were cultured according to the
supplier’s instructions. For oestrogen treatment, the media was
replaced with phenol red-free media supplemented with 10%
charcoal-stripped foetal bovine serum, 24h before stimulation;
10nM 17-b estradiol (E2) (Sigma) was added to the culture
medium 3h before harvesting.
The pCS3þMT containing hmi-er1a (Genbank: NM_001077704)
has been described elsewhere (Ding et al, 2003). pTRE-tight-
hmi-er1a was generated by inserting a BamHI–XhoI fragment
from pCS3þMT-hmi-er1a into BamHI–SalI cut pTRE-tight vector
(Clontech). The pcDNA3 vector containing hERa cDNA (Genbank:
NM_00125) was a gift from Dr Christine Pratt (University of
Ottawa). All plasmids were sequenced to verify the junctions and
the MI-ER1a or hERa sequence.
All transfections were performed as previously described (Ding
et al, 2003) in 6-well plates, using 1.6mg of plasmid DNA. A total of
10
5 cells per well were seeded 18h before transfection and cells
were harvested after 48h in culture.
Antibodies
The MI-ER1a antibody is a rabbit polyclonal antibody directed
against a synthetic peptide representing alpha-specific sequence
(amino acids 413–426); its production has been described and its
specificity has been determined previously (Paterno et al, 2002;
Thorne et al, 2008). Purified IgG was prepared from pre-immune
or immune serum using the Melon Gel IgG purification kit (Pierce,
Rockford, IL, USA) according to the manufacturer’s instructions.
Anti-ERa antibodies (D-12 and HC-20) were purchased from Santa
Cruz Biotechnology Inc. (Santa Cruz, CA, USA).
Co-immunoprecipitation and Western blot analysis
For the co-immunoprecipitation (co-IP) assays, either 1 10
6 non-
transfected MCF-7 cells or 2 10
5 HEK293 cells co-transfected with
pcDNA3-era and either pCS3þMT or pCS3þMT-mier1a were
used per sample. Cells were lysed as shown by Ding et al (2003) and
subjected to immunoprecipitation and western blotting as shown by
Ryan and Gillespie (1994). For determination of expression levels,
cells were lysed directly into SDS–PAGE loading buffer and
equivalent amounts of protein analysed by western blot as above.
Establishment of stably transfected T47D cell clones and
doxycycline induction
Generation of MI-ER1a Tet-On T47D cell clones was done as
described by Ding et al (2004), using a pTRE-tight-hmi-er1a
construct. Control cell lines were generated by transfection with
the pTRE-tight empty vector. Stable clones were induced to
express MI-ER1a using 2mgml
 1 doxycycline (dox) and expres-
sion was verified by western blot analysis of whole cell extracts,
using our anti-MI-ER1a-specific antibody (Paterno et al, 2002).
Colony formation in soft agar
A total of 2 10
4 cells were plated in 0.35% agarose on a layer of
0.5% agarose, prepared ±2mgml
 1 dox, ±10nM E2; controls
included the equivalent volume of buffer and/or ethanol. Media,
dox and E2 were replenished every 4 days and colonies were
stained with crystal violet after 18 days and counted.
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Figure 1 MI-ER1a interacts with ERa in vivo.( A) HEK293 cells were
transfected with pcDNA3-hera and either pCS3þMT-mier1a (lanes 3 and
4) or control empty vector (lanes 1 and 2) and treated with vehicle (lanes1
and 3) or 10nM E2 (lanes 2 and 4) for 3h before extraction. Extracts were
subjected to immunoprecipitation with anti-ERa (top panel) or loaded
directly onto the gel (middle and bottom panels). Western blots were
stained for MI-ER1a (top and middle panels) or ERa (bottom panel). (B)
Extracts from MCF-7 cells treated with vehicle (lanes 1, 3 and 5) or 10nM
E2 (lanes 2, 4 and 6) were subjected to IP with anti-mier1a (lanes 1 and 2),
pre-immune (lanes 3 and 4) or loaded directly onto the gel (lanes 5 and 6);
Western blotting was performed with anti-ERa.
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This study was approved by the Human Investigations Committee
at Memorial University (HIC approval no. 05.56). One hundred
and ten cases of primary invasive ductal carcinoma were identified
from the database of the NL Eastern Health Cancer Registry for the
years 2005 and 2006. Hematoxylin-and–eosin-stained slides for
each case were reviewed by a pathologist (B. Carter) and all well-
fixed tumour samples that contained adjacent normal ductal
epithelium were selected for this study. One formalin-fixed,
paraffin-embedded tissue block from each case was retrieved from
the archives of the Department of Pathology and Laboratory
Medicine, Memorial University, upon approval from Eastern
Health’s Medical Advisory and Board of Trustees Research
Proposal Approval Committee.
Tissue microarrays, whole tissue sections and
immunohistochemistry
The MI-ER1a protein expression pattern was examined both in TMAs
and in whole tissue sections. The tissue microarrays (TMAs) enabled
us to compare a large number of samples under identical staining
conditions, whereas whole tissue sections allowed us to examine
larger areas of tumour and normal tissue from a single sample.
Sections of human adrenal gland and small intestine were
purchased from US Biomax Inc. (Rockville, MD, USA). Micro-
arrays were purchased from US Biomax Inc., Biochain (Hayward,
CA, USA) and the Cooperative Human Tissue Network (http://
chtn.nci.nih.gov). Fourteen different TMAs containing a total of
204 normal, 91 hyperplasia, 78 DCIS, 102 ILC and 343 IDC samples
were stained. Any cores that were of questionable pathology were
reviewed by a pathologist. Some of the samples could not be
assessed as either the core was missing or contained insufficient
relevant tissue. The number of cases that were scored in each
category is listed in the Results section.
Immunohistochemistry and preabsorption with peptide was
performed as described previously (Thorne et al, 2008) using the
Universal LSAB
þ-HRP kit (Dako, Denmark) and 1.25mgml
 1 of
anti-MI-ER1a IgG or pre-immune IgG. Antigen retrieval was
performed in 10mM sodium citrate, pH 6.0, in a 951C water bath.
Optimum retrieval time was determined empirically to be 40min
for whole tissue sections and 30min for TMAs. As a control, each
batch included slides stained with pre-immune IgG. Each sample
was evaluated for staining using the Allred scoring system (Allred
et al, 1993; Harvey et al, 1999), which consists of a combined
score for staining intensity (0¼no, 1¼weak, 2¼moderate and
3¼intense staining) and proportion of positive cells (0¼0,
1¼o1/100, 2¼1/100–1/10, 3¼1/10–1/3, 4¼1/3–2/3, 5¼42/3
stained). The sum of the two produces an Allred score; the value
for the tumour cells was compared with that of normal adjacent
tissue. For the assessment of nuclear staining, samples were scored
positive if at least 5% of the nuclei in the section were stained;
however, the majority of normal samples that scored positive
contained at least 50% positive nuclei, whereas the majority of
positive tumour samples contained fewer than 10% positive nuclei.
Statistical analysis
Correlation between the relative intensity of MI-ER1a staining in
tumour sections and various clinicopathological parameters was
subjected to w
2 analysis (Pearson’s test, two-tailed, 95% confidence
interval) using SPSS v.13.0 software. The percentage of nuclear
staining in the carcinoma samples was compared with that in
normal breast tissue using a two-sided Fisher’s exact test and the
InStat v.3.0 software program (GraphPad Software, San Diego, CA,
USA).
RESULTS
MI-ER1a interacts with ERa in vivo
We investigated the ability of MI-ER1a to physically associate with
ERa in HEK293 cells transfected with mi-er1a and era, using co-IP
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Figure 2 Overexpression of MI-ER1a reduces anchorage-independent growth of T47D breast carcinoma cells. Control (TDc22)- or MI-ER1a (TDa5 and
TDa7)-expressing Tet-On T47D clones were cultured in 0.35% agarose, in the presence or absence of 2mgml
 1 dox and in the presence or absence of
10nM E2, as described in the Materials and methods. Colonies were stained with crystal violet, and colony size was measured using an ocular micrometre. A
minimum of six fields from each plate was analysed; the number of colonies larger than 100mm in size, expressed as a percentage of the total number of
colonies, was recorded for each treatment. (A) Representative fields for each treatment combination for each clone are shown. (B) Histogram showing the
average values and error bars for three independent experiments, performed in duplicate. (C) Western blot analysis to verify dox-specific induction of MI-
ER1a expression. A representative blot of extracts from TDc22, TDa5 and TDa7 cells, cultured in the absence (lanes 1, 3 and 5) or presence (lanes 2, 4 and
6) of 2mgml
 1 dox, is shown. The position of MI-ER1a is indicated.
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sassays. Our results show that ERa co-immunoprecipitates with MI-
ER1a both in the presence and absence of ligand (E2); however, the
intensity of the interaction was slightly reduced in the presence of
ligand (Figure 1A). This difference was not due to variability in the
expression levels of MI-ER1a or ERa, as these remained constant
(Figure 1A).
To verify that endogenous MI-ER1a interacts with endo-
genous ERa, co-IP analysis of extracts from an ERþ breast
carcinoma cell line, MCF-7, was performed using our anti-MI-
ER1a antibody. As can be seen in Figure 1B, ERa was detected in
the MI-ER1a immunoprecipitate (lanes 1 and 2), but not in the
pre-immune immunoprecipitate (lanes 3 and 4), demonstrating
a specific interaction between MI-ER1a and ERa. As seen in the
HEK293 cells, this interaction was stronger in the absence of
E2 (Figure 1B, lanes 1 and 2). These results demonstrate that
endogenous complexes containing MI-ER1a and ERa exist in
the cell.
MI-ER1a reduces E2-stimulated growth of ERþ breast
carcinoma cells
To investigate the functional effect of MI-ER1a-ERa interaction on
cellular responses to E2, we produced dox-inducible MI-ERa T47D
clonal cell lines. Control (TDc22) and MI-ER1a-expressing (TDa5
and TDa7) clones were assessed for their ability to proliferate in soft
agar, when stimulated by E2. In the absence of dox, E2 stimulated
the growth of both control and MI-ER1a clones, as measured by the
increase in colony diameter (Figure 2A and B). However, induction
of MI-ER1a expression by exposure to 2mgml
 1 dox dramatically
reduced the ability of E2 to stimulate colony growth, although
having no effect on the growth of TDc22 control cells (Figure 2A and
B). Dox induction of MI-ER1a expression in the clones was verified
by western blot analysis (Figure 2C). These results demonstrate that
MI-ER1a reduces E2-stimulated anchorage-independent growth of
breast carcinoma cells.
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Figure 3 Immunohistochemical staining with anti-MI-ER1a. Human breast tumour sections were stained with pre-immune IgG (A), anti-mier1a IgG (B)
or anti-mier1a IgG that had been pre-incubated with the a-specific peptide (C) or a control peptide (D). Note that only the peptide used to generate the
antibody blocks staining. Sections of normal human adrenal gland (E) and normal human small intestine (F) stained with anti-mier1a IgG served as positive
and negative tissue controls, respectively. Panel E shows a portion of the adrenal cortex that includes part of the zona glomerulosa (ZG) and zona fasciculata
(ZF), whereas Panel F shows a section through the ileum that includes lymphoid tissue (Peyer’s patch (PP)) and crypts of Lieberku ¨hn (C). Scale bar¼50mm
for A–D and 100mm for E and F.
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breast and breast carcinoma
The MI-ER1a antibody used in this study has been well
characterised and shown to be specific for the MI-ER1a protein
(Paterno et al, 2002; Thorne et al, 2008). For this study, we used
purified anti-MI-ER1a IgG and performed initial tests to confirm
the specificity of antibody staining on paraffin sections of human
tissue. Sections of breast tumours were stained in parallel with pre-
immune IgG (Figure 3A), anti-MI-ER1a IgG (Figure 3B), anti-MI-
ER1a IgG, which had been preabsorbed with the a-peptide used to
generate the antibody (Figure 3C) or with an unrelated peptide
(control peptide; Figure 3D). As can be seen in Figure 3,
preabsorption of the antibody with the a-peptide blocked staining
and produced results very similar to that obtained with pre-
immune IgG. The control peptide, on the other hand, did not affect
antibody binding, and the staining was similar to that obtained
with the anti-MI-ER1a IgG alone. Additional positive and negative
controls included sections of normal human adrenal cortex and
small intestine, respectively; previously, we reported positive
staining in the murine adrenal gland, whereas most areas of the
small intestine were negative (Thorne et al, 2008). As can be seen
in Figure 3E and F, staining of the human tissues was similar to
that seen in the mouse, with intense staining of the adrenal cortex
and no immunoreactivity in the ileum.
Of the TMAs used in this study, the cores that contained
sufficient tissue for assessment included 180 cases of normal
breast, 81 hyperplasia, 71 DCIS, 325 IDC and 99 ILC. In addition,
there were 16 cores containing lymph node metastases. An
additional 85 cases of IDC and adjacent normal breast tissue were
examined in whole tissue sections.
First, we determined the MI-ER1a expression pattern. In normal
breast tissue, staining was observed primarily in the ductal
epithelial cells (Figure 4G–I); there was some weaker staining of
vascular endothelial cells (inset in Figure 4H) but very little or no
staining of the stroma. Some variability was observed in the
intensity of staining of the ductal epithelium and no obvious
difference in staining intensity of the ducts vs the lobules. In the
AB C
GH I
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J K L
Figure 4 Expression pattern of MI-ER1a in normal breast tissue and invasive ductal carcinoma. (A–C) Low magnification of representative examples of
primary invasive ductal carcinoma. (D–F) High magnification of IDC illustrating the subcellular localisation of MI-ER1a. Note that the nuclei (arrowheads)
are negative (blue) and that MI-ER1a expression (brown) is exclusively cytoplasmic. (G–I) Low magnification of representative examples of normal breast
tissue. MI-ER1a expression is detected primarily in the ducts with little or no expression in the surrounding stroma. The inset in H shows a higher
magnification of the blood vessel indicated by a long arrow and illustrates weak staining of endothelial cells (arrowhead). (J–L) High magnification of normal
ducts. Arrows indicate nuclear MI-ER1a staining; arrowheads indicate examples of negative nuclei. Scale bar¼250mm for A–C and G–I,2 5mm for D–F,
J–L and inset in H.
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stumours, the staining pattern was similar to that in normal tissue,
with expression in the tumour cells themselves and little or no
staining of the stroma (Figure 4A–C).
Next, staining in whole tissue sections was assessed using the
Allred scoring system, which consists of a combined score for
intensity level (0–3) and proportion of positive cells (0–5). The
Allred score for the tumour was compared with that for adjacent
normal tissue. Overall, there was no consistent difference in scores
between the tumour and adjacent normal tissue, that is, some
tumours had lower values than adjacent normal, some had higher
values and some had equal values. These three categories of
relative Allred scores were analysed for correlation with a number
of clinical parameters, which included patient age, tumour size,
lymph node status, grade (modified Scarff–Bloom–Richardson),
stage (TNM), ER, PR and Her2/neu status (Table 1). No statistically
significant correlation was found, as determined by w
2 analysis
(Table 1). In addition, we analysed the intensity and proportion
scores separately and found no statistically significant correlation
(data not shown).
Samples were also examined for the subcellular localisation
of MI-ER1a and initially scored as nuclear only, cytoplasmic only
or nuclear and cytoplasmic. As virtually all samples had some
cytoplasmic staining but the presence of nuclear staining was
limited, samples were then separated into two categories: nuclear
Table 1 Analysis of correlation between clinicopathological parameters and relative MIER1a staining in breast carcinoma
MIER1 expression:
a tumor Allred score vs normal Allred score
Parameters Less than normal Equal to normal Greater than normal Total P-value
b
Age
o50 6 (19.4) 4 (12.9) 21 (67.7) 31
4¼50 8 (10.1) 16 (20.3) 55 (69.6) 79 P¼0.410
Age
o¼44 5 (25.0) 3 (15.0) 12 (60.0) 20
44–64 4 (7.5) 9 (17.0) 40 (75.5) 53
4¼65 5 (13.9) 8 (19.4) 24 (66.7) 37 P¼0.365
Tumor size (TNM)
T1 6 (10.2) 11 (18.6) 42 (71.2) 59
T2 7 (16.7) 6 (14.3) 29 (69.0) 42
T3 and T4 1 (11.1) 3 (33.3) 5 (55.6) 9 P¼0.618
Tumor size (categorical)
o¼2cm 6 (10.2) 11 (18.6) 42 (71.2) 59
42cm 8 (15.7) 9 (17.6) 34 (66.7) 51 P¼0.693
Lymph node involvement
No 6 (13.6) 9 (20.5) 28 (63.6) 43
Yes 4 (12.5) 6 (18.8) 22 (68.8) 32 P¼0.957
Lymph node status (TNM)
N0 6 (13.6) 9 (20.5) 28 (63.6) 43
N1 4 (16.0) 5 (20.0) 16 (64.0) 25
N2 0 (0) 0 (0) 6 (100.0) 6
N3 0 (0) 0 (0) 1 (100.0) 1 P¼0.941
Grade
c
1 6 (20.0) 8 (26.7) 16 (53.3) 30
2 5 (11.9) 8 (19.1) 29 (69.0) 42
3 3 (8.1) 4 (10.8) 30 (81.1) 37 P¼0.217
Stage
d
I 1 (4.0) 6 (24.0) 18 (72.0) 25
II 9 (23.1) 4 (10.3) 26 (66.6) 39
III 0 (0) 3 (27.3) 8 (72.7) 11
IV 0 0 0 0 P¼0.082
ER
Negative 2 (12.5) 2 (12.5) 12 (75.0) 16
Positive 10 (11.2) 16 (18.0) 63 (70.8) 89 P¼0.891
PR
Negative 3 (10.8) 2 (7.1) 23 (82.1) 28
Positive 9 (11.8) 15 (19.7) 52 (68.4) 76 P¼0.300
HER2/neu status
Negative 10 (13.5) 15 (20.3) 49 (66.2) 74
Positive 1 (6.7) 0 (0) 14 (93.3) 15 P¼0.086
aValues are listed as number of subjects, with percentage listed in brackets.
bP-value; w
2 analysis (Pearson’s test, two-tailed, 95% CI), statistical significance is assumed when
Po0.05.
cModified Scarff–Bloom–Richardson grading system.
dFIGO staging system.
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sstaining and no nuclear staining. The results were quite striking,
showing a large differential between the percentage of normal
tissue samples and IDC that were positive for nuclear staining: 74.7
vs 4.4%, respectively (Po0.0001; Figures 4D–F, 4J–L, 5A). In
addition, the proportion of stained nuclei within a sample was
different: most tumour samples that displayed nuclear MI-ER1a
contained fewer than 10% stained nuclei, whereas the majority of
normal samples contained 450% stained nuclei. A differential in
nuclear staining between normal and ILC was observed as well
(74.7 vs 25.3%; Po0.0001; Figure 4A). We examined nuclear
staining in other subtypes, namely hyperplasia and DCIS. The
percentage nuclear staining in hyperplasia was similar to that of
normal samples (76.5%; P¼0.8831; Figure 5A), whereas DCIS was
intermediate between normal and IDC (50.7%; P¼0.0001;
Figure 5A). Cases of lymph node metastases from patients with
IDC showed levels of nuclear staining similar to IDC (6.3%;
P¼0.5009; Figure 5A).
It was important to compare nuclear staining in tumour samples
with adjacent normal tissue from the same patient, to ensure that
the observed difference in MI-ER1a subcellular localisation is not
merely due to individual patient differences. Therefore, we
analysed 58 cases from TMAs that contained matched tumour–
normal cores (Figure 5B); in addition, we compared tumour and
normal adjacent areas in whole tissue sections from 85 cases of
IDC (Figure 5C). Both gave results similar to that described above:
the majority of tumours lacked nuclear staining, whereas most of
the adjacent normal areas showed nuclear staining (Figure 5B
and C). Together, these data demonstrate that a shift in the
subcellular localisation of MI-ER1a is associated with breast cancer
progression.
DISCUSSION
Our demonstration that MI-ER1a can physically interact with ERa
and that regulated overexpression of MI-ER1a dramatically affects
oestrogen-stimulated growth of breast carcinoma cells indicates
that MI-ER1a functions as an ER corepressor. A number of ERa
corepressors have been identified (Hall and McDonnell, 2005) and
MI-ER1 is similar in structure and function to other known NR
corepressors, including NCoR (Horlein et al, 1995), SMRT (Chen
and Evans, 1995) and MTA1–3 (Manavathi and Kumar, 2007),
which also recruit HDAC activity to repress transcription.
Traditionally, corepressors bind unliganded NRs, whereas
coactivators bind liganded NRs; however, ERa is distinct from
other NRs in this regard (Dobrzycka et al, 2003). For example,
the classic corepressors, NCoR (Horlein et al, 1995) and SMRT
(Chen and Evans, 1995), interact only with antagonist-bound ERa,
whereas LCoR interacts with ERa only in the presence of oestrogen
(Fernandes et al, 2003). Our results show that MI-ER1a binds ERa
in the presence and absence of oestrogen and, in this regard, is
similar to BRCA1, which regulates both oestrogen-stimulated and
unliganded ERa activity (Fan et al, 2001; Rosen et al, 2005).
Previously, we reported a PCR analysis that demonstrated a
significant increase in mi-er1 mRNA expression levels in breast
tumours when compared with normal breast tissue (Paterno et al,
1998). However, our current study shows no consistent difference
in MI-ER1a protein expression levels. This discrepancy is most
likely due to the fact that MI-ER1a expression in normal tissue is
restricted primarily to ductal epithelial cells, whereas within the
tumour, virtually all tumour cells are positive for MI-ER1a. Thus,
the proportion of cells expressing mi-er1 mRNA per volume of
tissue would be much lower in normal breast than in a solid
tumour sample.
Our immunohistochemical analysis showed that although
virtually all (96%) IDC samples have lost nuclear MI-ER1a, only
half of the DCIS samples showed this shift in subcellular
localisation. Ductal carcinoma in situ consists of a heterogeneous
group of pre-invasive lesions that may or may not progress to IDC
and, at the moment, it is not possible to accurately predict which
patients are at risk (Wiechmann and Kuerer, 2008). Thus, it will be
important to determine the value of MI-ER1a as a prognostic
indicator, using a larger sample size. A key question is whether loss
of nuclear MI-ER1a is associated with specific subtypes of DCIS or
any other parameter correlated with progression to IDC. Such
parameters include histological criteria, for example, nuclear grade
and cell necrosis, as well as molecular markers, for example, loss of
IGFBP-rP1 expression (Wiechmann and Kuerer, 2008). As more
prognostic markers are identified, it may become possible to
define a molecular-histological fingerprint for DCIS that can
accurately predict a patient’s risk of recurrence as invasive
carcinoma.
Our observations in this study are consistent with a model
where, in the progression to IDC, MI-ER1a is shuttled to the
cytoplasm such that it cannot exert its gene/chromatin repressor
functions. This may include loss of the functional interaction
between MI-ER1a and ERa. Alternatively, it may act in a manner
similar to MTA1s, a splicing isoform of MTA1, which binds to ERa
in the cytoplasm and enhances ERa non-genomic activities,
including stimulation of peptide growth factor signal transduction
pathways (Kumar et al, 2002). The net result is an increase in
breast carcinoma cell proliferation. We are currently investigating
the molecular mechanisms of MI-ER1a localisation in breast
cancer cells and its role in tumour progression to an invasive
phenotype.
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Figure 5 Loss of nuclear MI-ER1a during breast cancer progression. (A)
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